Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up - Scorecard - MDSpire
Advertisement
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Clinical Scorecard: Correction: Analysis of Brentuximab Vedotin Combined with Chemotherapy for Initial Treatment of Systemic Anaplastic Large Cell Lymphoma: 5-Year Follow-Up from the ECHELON-2 Study Subgroup
At a Glance
Category
Detail
Condition
Systemic Anaplastic Large Cell Lymphoma (sALCL), ALK-negative subtype
Key Mechanisms
Brentuximab vedotin combined with chemotherapy (A + CHP) versus standard CHOP chemotherapy
Target Population
Patients with ALK-negative systemic anaplastic large cell lymphoma achieving complete response
Care Setting
Oncology and hematology clinical treatment settings
Key Highlights
Correction clarifies 5-year progression-free survival (PFS) rates pertain to patients with ALK– sALCL who achieved complete response (CR).
Estimated 5-year PFS rates in ALK– sALCL patients with CR were 56.8% for A + CHP arm and 56.0% for CHOP arm.
Data for 5-year PFS in ALK– sALCL patients regardless of response are available in the original article's Figure 1.
Guideline-Based Recommendations
Diagnosis
Diagnosis of systemic anaplastic large cell lymphoma should include ALK status determination.
Management
Consider brentuximab vedotin combined with chemotherapy (A + CHP) as front-line treatment for systemic ALCL.
Monitor treatment response to identify patients achieving complete response.
Monitoring & Follow-up
Assess progression-free survival at intervals including 5 years post-treatment.
Monitor patients closely for disease progression regardless of initial response.
Risks
Potential misinterpretation of survival data if response status is not clearly specified.
Patient & Prescribing Data
Patients with ALK-negative systemic anaplastic large cell lymphoma undergoing initial treatment
5-year PFS rates are similar between A + CHP and CHOP arms in patients achieving complete response, highlighting importance of response status in outcome interpretation.
Clinical Best Practices
Clearly specify patient response status when reporting survival outcomes to avoid misinterpretation.
Use brentuximab vedotin plus chemotherapy as a treatment option in ALK-negative sALCL with consideration of patient response.
Refer to detailed subgroup data for comprehensive understanding of long-term outcomes.
by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage
